Next Article in Journal
A Novel Lid-Covering Peptide Inhibitor of Nicotinic Acetylcholine Receptors Derived from αD-Conotoxin GeXXA
Previous Article in Journal
Running the Stop Sign: Readthrough of a Premature UAG Termination Signal in the Translation of a Zebrafish (Danio rerio) Taurine Biosynthetic Enzyme
Previous Article in Special Issue
Pharmacophore-Based Virtual Screening of Novel Inhibitors and Docking Analysis for CYP51A from Penicillium italicum
Article Menu
Issue 6 (June) cover image

Export Article

Open AccessArticle
Mar. Drugs 2017, 15(6), 163;

Xyloketal B Attenuates Fatty Acid-Induced Lipid Accumulation via the SREBP-1c Pathway in NAFLD Models

Institute of Biomedicine & Guangdong Provincial Key Laboratory of Bioengineering Medicine, Jinan University, Guangzhou 510632, China
Department of Pharmacy, Jinan University, Guangzhou 510632, China
School of Chemistry and Chemical Engineering, Sun Yat-Sen University, Guangzhou 510275, China
The People’s Hospital of Shenzhen City, Shenzhen 518020, China
Authors to whom correspondence should be addressed.
Academic Editors: Antonio Trincone, Se‐Kwon Kim and Peer B. Jacobson
Received: 8 February 2017 / Revised: 27 May 2017 / Accepted: 1 June 2017 / Published: 3 June 2017
Full-Text   |   PDF [1274 KB, uploaded 23 June 2017]   |  


The goal of this study was to examine the effects of xyloketal B on nonalcoholic fatty liver disease (NAFLD) and to explore the molecular mechanisms underlying its effects in both in vivo and in vitro models. We discovered an association between xyloketal B and the sterol regulatory element-binding protein-1c (SREBP-1c) signaling pathway, which is related to lipid metabolism. Mice were dosed with xyloketal B (5, 10 and 20 mg/kg/d) and atorvastatin (15 mg/kg/d) via intraperitoneal injection once daily for 40 days after being fed a high fat diet plus 10% high fructose liquid (HFD+HFL) for 8 weeks. Xyloketal B significantly improved HFD+HFL-induced hepatic histological lesions and attenuated lipid and glucose accumulation in the blood as well as lipid accumulation in the liver. Xyloketal B increased the expression of CPT1A, and decreased the expression of SREBP-1c and its downstream targeting enzymes such as ACC1, ACL, and FAS. Xyloketal B also significantly reduced lipid accumulation in HepG2 cells treated with free fatty acids (FFAs). These data suggested that xyloketal B has lipid-lowering effects via the SREBP-1c pathway that regulate lipid metabolism. Thus, targeting SREBP-1c activation with xyloketal B may be a promising novel approach for NAFLD treatment. View Full-Text
Keywords: Xyloketal B; NAFLD; SREBP-1c pathway Xyloketal B; NAFLD; SREBP-1c pathway

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Zhang, Y.; Meng, T.; Zuo, L.; Bei, Y.; Zhang, Q.; Su, Z.; Huang, Y.; Pang, J.; Xiang, Q.; Yang, H. Xyloketal B Attenuates Fatty Acid-Induced Lipid Accumulation via the SREBP-1c Pathway in NAFLD Models. Mar. Drugs 2017, 15, 163.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top